Takeda Pharmaceutical and enGene, a privately held biotechnology company, announced a new strategic alliance.
Here are five things to notes:
1. Through the alliance, the company aims to develop and commercialize novel therapies for specialty gastrointestinal diseases using enGene's gene delivery platform, Gene Pill.
2. Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda.
3. Takeda will have an option to exclusively license the global rights for the product candidates.
4. Following option exercise, Takeda will be responsible for all clinical development and commercialization of those products.
5. Takeda will also collaborate with enGene to develop the Gene Pill into a platform for oral delivery of antibodies.